BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF), which is developing targeted treatments with fewer side-effects, said it had made significant progress with its BVX002 programme, targeting solid tumour indications with a focus on ovarian cancer.
Specifically, it has successfully selected the final antibody sequences for BVX002, a first-in-class antibody drug conjugate (ADC), positioning it to identify a development lead in 2024.
In preclinical models, BiVictriX has confirmed the efficacy and selectivity of these sequences. They demonstrate strong effectiveness against targeted cancer cells compared to non-target cells, passing early developability assessments.
Emerging data, derived from primary patient samples using advanced sequencing techniques and laboratory profiling, indicate that the antigen fingerprint targeted by BVX002 is prevalent in various solid tumour types.
Notably, it is highly present in high-grade serous ovarian cancer, found in over 86% of patient samples. This discovery highlights the significant unmet medical need and commercial potential for BVX002 in treating ovarian cancer.
"ADCs have demonstrated incredible promise as an alternative therapeutic option to current monotherapies and combination therapies across difficult-to-treat cancers, backed by high specificity, versatility and selectivity," said BiVictriX CEO Tiffany Thorn.
"We have been encouraged by BiVictriX's progress to date in our lead BVX001 programme for the treatment of acute myeloid leukaemia and are also pleased by the further development and expansion of our proprietary ADC pipeline, where BVX002 is showing early promise in targeting high-grade serous ovarian carcinoma, which accounts for 75% of epithelial ovarian cancers.
"We expect to identify a lead development candidate for BVX002 in 2024 and look forward to providing our shareholders with further updates as appropriate."
An updated version of BiVictriX's corporate presentation, detailing these developments, is now available on the company's website.